ASCO GI 2021 | DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the ongoing DESTINY-Gastric03 study (NCT04379596), a Phase Ib/II, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer. T-DXd is an antibody-drug conjugate containing an anti-HER2 antibody, which in Phase I studies, has shown promising antitumor activity. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).